[
  {
    "ts": null,
    "headline": "Arcturus: Downgrading As mRNA Promise Meets Market Reality",
    "summary": "Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.",
    "url": "https://finnhub.io/api/news?id=3ce38d4278776c5ef1a0f6e172ac675d6cb4339cb2e51e61da034007ac20ecc7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738082899,
      "headline": "Arcturus: Downgrading As mRNA Promise Meets Market Reality",
      "id": 132488368,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157332358/image_2157332358.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.",
      "url": "https://finnhub.io/api/news?id=3ce38d4278776c5ef1a0f6e172ac675d6cb4339cb2e51e61da034007ac20ecc7"
    }
  }
]